A trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy

ISRCTN ISRCTN16465571
DOI https://doi.org/10.1186/ISRCTN16465571
EudraCT/CTIS number 2012-003835-40
Secondary identifying numbers 13741
Submission date
26/03/2013
Registration date
26/03/2013
Last edited
21/06/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/trials-search/a-trial-looking-at-cabazitaxel-for-prostate-cancer-that-has-started-to-get-worse-after-having-hormone-therapy-and-docetaxel-cantata

Contact information

Mr Nick Martin
Scientific

Cancer Research UK Clinical Trials Unit
Institute for Cancer Studies
Edgbaston
Birmingham
B15 2TT
United Kingdom

Email CANTATA@trials.bham.ac.uk

Study information

Study designRandomised; Interventional; Design type: Treatment
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleA multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy
Study acronymCANTATA
Study objectivesThis study compares the safety and levels of activity of cabazitaxel versus docetaxel re-challenge in patients with metastatic castrate refractory prostate cancer who have been previously exposed to combined docetaxel and androgen deprivation as first-line treatment for advanced prostate cancer.

The difference between treatment arms in terms of the number of patients who have a clinical event (clinical progression or death) will provide the evidence whether the levels of activity of cabazitaxel warrant further investigation in a phase III trial.
Ethics approval(s)Liverpool Central -– North West NRES Committee, 10/12/2012, ref: 12/NW/0792
Health condition(s) or problem(s) studiedProstate cancer
InterventionPatients will be randomised to one of the following two treatments (plus 10mg prednisolone daily in either regimen):
1. Cabazitaxel 25mg/m2 3 weekly plus prednisolone for up to 10 cycles
2. Docetaxel 75mg/m2 3 weekly plus prednisolone for up to 10 cycles

Follow Up Length: 24 month(s)
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Cabazitaxel, docetaxel
Primary outcome measureClinical progression-free survival (CPFS)
Secondary outcome measuresNo secondary outcome measures
Overall study start date07/03/2013
Completion date29/04/2016

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexMale
Target number of participantsPlanned Sample Size: 138; UK Sample Size: 138; Description: Target recruitment is 138 patients in total, with 69 patients per arm.
Total final enrolment15
Key inclusion criteria1. Diagnosis of histologically proven prostate adenocarcinoma, that is castrate refractory
2. Previously treated with up to 6 cycles of Docetaxel at the same time (defined as commencing within 3 months) as instigation of primary hormone therapy.
3. Confirmed biochemical, radiological or clinical progression.
4. Metastatic disease
5. Male and female, aged 18 or over
6. WHO performance status grade 0 to 2
7. Adequate organ function as evidenced by:
7.1. ANC >1.5 x109/L
7.2. WBC >3.0 x109/L
7.3. Haemoglobin >10g/dL
7.4. Platelet count > 100 x10^9L
7.5. Total bilirubin <1.0 xULN
7.6. AST/ ALT <1.5 xULN
7.7. GFR >30ml/min (calculated by EDTA clearance, 24h urine collection, or Cockcroft-Gault)
8. Available for long-term follow up
9. Patient’s written informed consent
Key exclusion criteria1. Prior systemic therapy with other chemotherapy drugs
2. Metastatic brain disease or leptomeningeal disease
3. Patients with bilirubin equal to or greater than 1.0 xULN
4. Previous extensive palliative radiotherapy to bone marrow, e.g. hemibody radiotherapy
5. Active grade >=2 peripheral neuropathy (NCI CTC v 4)
6. Active infection requiring systemic antibiotic or antifungal medication
7. Patients with reproductive potential not implementing accepted and effective method of contraception
Date of first enrolment07/03/2013
Date of final enrolment12/01/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

The Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH
United Kingdom

Sponsor information

University of Birmingham (UK)
University/education

Edgbaston
Birmingham
B15 2TT
England
United Kingdom

Website http://www.birmingham.ac.uk/researchsupportgroup
ROR logo "ROR" https://ror.org/03angcq70

Funders

Funder type

Industry

Aventis Pharma Ltd T/A Sanofi-Aventis

No information available

Cancer Research UK (UK)
Private sector organisation / Other non-profit organizations
Alternative name(s)
CR_UK, Cancer Research UK - London, CRUK
Location
United Kingdom

Results and Publications

Intention to publish date31/12/2017
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryStored in repository
Publication and dissemination planResults of this trial will be submitted for publication in a peer-reviewed journal. The manuscript will be prepared by the Trial Management Group (TMG) and authorship will be determined by mutual agreement.
IPD sharing planThe datasets generated during and/or analysed during the current study will be stored in a publically available repository in 2017. Repository : European Medicines Agency (EMA)’s European Clinical Trial Database, EudraCT V10. URL : http://eudract.ema.europa.eu

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 21/06/2019 No No
HRA research summary 28/06/2023 No No

Editorial Notes

21/06/2019: Added clinicaltrialsregister.eu link to basic results (scientific). Added total final enrollment.
20/02/2017: The overall trial end date was changed from 12/02/2016 to 29/04/2016.
14/11/2016: The overall trial end date was changed from 30/06/2015 to 12/02/2016.